查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403395

透納氏症市場至2030年的預測：按類型、藥物類型、治療類型、診斷、給藥途徑、最終用戶和地區進行的全球分析

Turner Syndrome Market Forecasts to 2030 - Global Analysis By Type, Drug Type, Therapy Type, Diagnosis, Route Of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球透納氏症市場規模為 42.3 億美元，預計到2030年將達到 72.9 億美元，預測期內年複合成長率為 8.1%。

透納氏症是一種影響女性的染色體疾病，由 X 染色體缺失或不完整所引起。女性通常有兩條 X 染色體（XX），但透納氏症患者要麼缺少一條 X 染色體（X0），要麼其中一條 X 染色體出現異常。患有透納氏症的女孩通常具有特異性的身體特徵，例如身材矮小、網狀頸部（額外的皮膚褶皺）、寬闊的胸部、低位耳朵和高位上顎。

根據國家醫學圖書館2017年的資料，全球每 2,500 名新生兒中約有 1 名患有透納氏症。

提高患者的宣傳和意識

患者倡導在倡導改善醫療保健服務和治療的可近性方面發揮重要作用。它通常延伸到目的是改善透納氏症罕見疾病患者整體環境的政策舉措。提高認知通常可以早期發現透納氏症。他們在提高認知、支持研究和倡導更好的治療選擇方面發揮著重要作用。這些團體促進研究人員、臨床醫生和製藥公司之間的合作。

病患人數有限

透納氏症是一種罕見疾病，每 2,000 名女孩中就有 1 人受到影響。因此，幾乎沒有機會獲得對於了解疾病進展很重要的自然史資料。由於患者數量有限，很難收集足夠的真實世界證據，這可能會妨礙了解治療方法的長期效果。此外，確定治療方法價值並確保償付可能更加複雜。這些方面增加了複雜性並阻礙了市場成長。

未滿足的醫療需求

透納氏症是一種罕見疾病，有一些未滿足的醫療需求需要有效的標靶治療。解決這些未滿足的醫療需求需要醫療保健專業人員、研究人員和製藥公司之間的合作。標靶治療治療的發展可以顯著改善透納氏症的治療，並帶來更有效和個體化的治療選擇。製藥公司可能會將此視為開發創新治療方法和加速市場擴張的機會。

開發成本高

開發針對透納氏症罕見疾病的治療方法通常面臨獨特的挑戰，導致急劇上升的開發成本。由於潛在患者數量有限，製藥公司在經濟上很難投資開發透納氏症的藥物和治療方法。此外，了解潛在的遺傳機制，進行臨床前研究以及引導罕見疾病的監管流程需要專門的知識和資源。這些因素的結合可能會阻礙市場的成長。

COVID-19 的影響

全球醫療保健服務受到 COVID-19 疫情的嚴重影響。這場大流行已經轉移了資源並推遲了透納氏症非緊急醫療狀況的治療。患者在獲得常規檢查、治療和支持服務方面面臨挑戰。此外，製藥業的供應鏈經歷了中斷，影響了與透納氏症相關的藥品和其他醫療用品的供應。市場也已恢復至疫情前的水準。

預計 Genotropin 細分市場在預測期內將是最大的

估計 Genotropin 細分市場將出現良好的成長。 Genotropin 通常用作綜合治療方法的一部分，包括荷爾蒙替代療法和其他干預措施，以解決透納氏症的各個方面。 Genotropin 有助於改善透納氏症患者的生活品質。它具有許多好處，包括改善身體組成、骨骼健康、心血管健康、改善身材矮小和整體身體生長。

產前檢測領域預計在預測期內年複合成長率最高

預計產前檢測領域在預測期內將呈現最高的年複合成長率。產前檢測在透納氏症的早期診斷中發揮重要作用。這種早期診斷可能會導致及時介入和適當的管理策略，改善受影響個體的結果。了解懷孕期間的疾病可以幫助父母做好心理準備，並應對與疾病相關的挑戰。隨著技術和基因檢測的不斷進步，透納氏症的產前檢測將變得更加準確和方便，進一步增強其在患者照護和計劃生育中的作用。

佔有率最大的地區

由於人們對女性健康意識的提高，醫療保健支出的增加以及醫療保健行業的成長，預計亞太地區將在預測期內佔據最大的市場佔有率。印度的醫療保健產業是成長最快的產業之一。印度和中國等新興國家正大力投資醫療基礎設施、醫療專家和研發活動。因此，支出的增加加上女性遺傳疾病數量的定期增加，導致該地區透納氏症市場的成長。

年複合成長率最高的地區：

預計歐洲在預測期內的年複合成長率最高。歐洲是Novartis、psen和Sanofi-Genzyme等主要企業的所在地。這些公司大力投資罕見遺傳疾病的研究。這些公司通常提供最新的創新和解決方案。此外，罕見疾病領域不斷湧現的技術創新、龐大的患者群體、對唐氏症的認知不斷增強以及生物技術領域的成長推動該地區的市場成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球透納氏症市場：依類型

  • 馬賽克特納透納氏症
  • 經典透納氏症

第6章 全球透納氏症市場：依藥物類型

  • Oxandrolone
  • Oxandrin
  • Norditropin
  • Somatropin
  • Genotropin
  • Humatrope
  • Zomacton
  • Nutropin

第7章 全球透納氏症市場：依治療類型

  • 黃體酮替代療法
  • 雌激素替代療法
  • 生長激素治療
  • 心理治療
  • 其他治療方法

第8章 全球透納氏症市場：依診斷

  • 體檢
  • 核型分析
  • 產前檢測
    • 羊膜穿刺術
    • 超音波檢查
    • 絨毛膜絨毛取樣
  • 其他診斷

第9章 全球透納氏症市場：依給藥途徑

  • 口服
  • 皮下
  • 靜脈
  • 肌肉注射
  • 其他給藥途徑

第10章 全球透納氏症市場：依最終用戶分類

  • 調查機構
  • 醫院和診所
  • 學術機構
  • 其他最終用戶

第11章 全球透納氏症市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • Smiths Group
  • Pfizer Inc.
  • Rocket Medical PLC
  • Medtronic
  • Novo Nordisk
  • Sanofi
  • Cooper Pharma
  • Eli Lilly and Company
  • Genentech
  • Lupin Pharmaceuticals Inc
  • Sandoz International GmbH
  • AbbVie Inc.
  • Codexis
  • Merck & Co.
  • American Gene Technologies
  • Johnson & Johnson Services Inc
  • F. Hoffmann-La Roche Limited
  • Ultragenyx Pharmaceutical
  • Abbott Laboratories
  • BioMarin
Product Code: SMRC24620

According to Stratistics MRC, the Global Turner Syndrome Market is accounted for $4.23 billion in 2023 and is expected to reach $7.29 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Turner syndrome is a chromosomal condition that affects females and results from a missing or incomplete X chromosome. Typically, females have two X chromosomes (XX), but individuals with Turner syndrome have either a missing X chromosome (X0) or abnormalities in one of the X chromosomes. Girls with turner syndrome often have specific physical characteristics including short stature, a webbed neck (extra folds of skin), a broad chest, low-set ears, and a high-arched palate.

According to the National Library of Medicine in 2017, about 1 in 2,500 new-born girls, worldwide, were affected with the Turner Syndrome.

Market Dynamics:

Driver:

Rising patient advocacy and awareness

Patient advocacy plays a crucial role in advocating for improved access to healthcare services and treatments. It often extends to policy initiatives aimed at improving the overall landscape for individuals with rare diseases like turner syndrome. Increased awareness often leads to early detection of Turner syndrome. It plays a crucial role in raising awareness, supporting research, and advocating for better treatment options. These groups facilitates collaboration between researchers, clinicians, and pharmaceutical companies.

Restraint:

Limited patient population

Turner Syndrome is a rare disorder which occurs in mostly one out of 2000 girls. So, there is less availability of natural history data, which is crucial for understanding the progression of the disease. Limited patient numbers makes it challenging to gather sufficient real-world evidence, potentially hindering the understanding of the long-term impact of therapies. Also, establishing the value of a therapy and securing reimbursement can be more complex. This aspect raises the complexities and hampers the market growth.

Opportunity:

Unmet medical needs

Turner Syndrome is a rare disorder and it presents several unmet medical needs that need effective and targeted therapies. Addressing these unmet medical needs requires collaboration between healthcare professionals, researchers, and pharmaceutical companies. The development of targeted therapies could significantly improve the management of Turner Syndrome, potentially leading to more effective and personalized treatment options. Pharmaceutical companies may see this as an opportunity to develop innovative treatments which in turn accelerates the market expansion.

Threat:

High development costs

The development of therapies for rare conditions such as turner syndrome often faces unique challenges, leading to high development costs. The limited number of potential patients makes it economically challenging for pharmaceutical companies to invest in the development of drugs or therapies for turner syndrome. Also, understanding the underlying genetic mechanisms, conducting preclinical studies, and navigating the regulatory processes for rare diseases require specialized expertise and resources. The combination of these factors can hamper the growth of the market.

COVID-19 Impact

Global healthcare services have been severely impacted by the COVID-19 epidemic. Due to the pandemic, resources were redirected, which caused delays in the treatment of non-urgent medical disorders, such as Turner syndrome. Patients have faced challenges in accessing regular check-ups, treatments, and support services. Additionally, the supply chain for the pharmaceutical sector experienced interruptions that impacted the availability of drugs and other healthcare supplies related to Turner syndrome. The market has further recovered to its pre-pandemic level.

The genotropin segment is expected to be the largest during the forecast period

The genotropin segment is estimated to have a lucrative growth. Genotropin is often used as part of a comprehensive treatment approach that includes hormone replacement therapy and other interventions to address various aspects of turner syndrome. It contributes to an improved quality of life for individuals with turner syndrome. It exhibits numerous benefits such as improved body composition, bone health, cardiovascular health, improvement of short stature and overall body growth.

The prenatal testing segment is expected to have the highest CAGR during the forecast period

The prenatal testing segment is anticipated to witness the highest CAGR growth during the forecast period. Prenatal testing plays a crucial role in the early diagnosis of turner syndrome. This early diagnosis can lead to timely interventions and appropriate management strategies, potentially improving outcomes for the affected individual. Knowing about the disorder during pregnancy allows parents to emotionally prepare for the challenges associated with the condition. As technology and genetic testing methods continue to advance, the accuracy and accessibility of prenatal testing for turner syndrome are likely to improve, further enhancing its role in patient care and family planning.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increasing awareness for women health, rising healthcare expenditures and growing healthcare sector. The Indian healthcare sector was one of the fastest growing industries. The developing countries like the India and China are investing heavily on healthcare infrastructure, professional doctors and R&D activities. Therefore, the increasing expenditure coupled with rising regularity of genetic disorders in females leads to the growth of the turner syndrome market in this region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Europe is home to several key players such as Novartis, Ipsen and Sanofi Genzym. These companies invest hugely on research activities related to rare genetic diseases. They often bring out latest innovations and solutions. Further, rise in technological innovations for rare disorders, huge patient population, increasing awareness regarding down syndromes and growing biotechnology sector are boosting the region's market growth.

Key players in the market:

Some of the key players profiled in the Turner Syndrome Market include Smiths Group, Pfizer Inc., Rocket Medical PLC, Medtronic, Novo Nordisk, Sanofi, Cooper Pharma, Eli Lilly and Company, Genentech, Lupin Pharmaceuticals Inc, Sandoz International GmbH, AbbVie Inc., Codexis, Merck & Co., American Gene Technologies, Johnson & Johnson Services Inc, F. Hoffmann-La Roche Limited, Ultragenyx Pharmaceutical, Abbott Laboratories and BioMarin.

Key Developments:

In October 2023, Novo Nordisk, a subsidiary of Novo Holdings AS, unveils Somapacitan (Sogroya) is a human growth hormone analog. It is formulated as solution for subcutaneous route of administration. Sogroya is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (GHD).

In March 2023, Sanofi and Provention Bio Inc, have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc. The acquisition is a strategic fit for Sanofi at the intersection of the company's growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet need, and its expertise in diabetes.

Types Covered:

  • Mosaic Turner Syndrome
  • Classical Turner Syndrome

Drug Types Covered:

  • Oxandrolone
  • Oxandrin
  • Norditropin
  • Somatropin
  • Genotropin
  • Humatrope
  • Zomacton
  • Nutropin

Therapy Types Covered:

  • Progesterone Replacement Therapy
  • Oestrogen Replacement Therapy
  • Growth Hormone Therapy
  • Psychological Therapy
  • Other Therapy Types

Diagnosis Covered:

  • Physical Examination
  • Karyotyping
  • Prenatal Testing
  • Other Diagnosis

Route Of Administrations Covered:

  • Oral
  • Sub-cutaneous
  • Intravenous
  • Intramuscular
  • Other Route Of Administrations

End Users Covered:

  • Research Organizations
  • Hospitals & Clinics
  • Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Turner Syndrome Market, By Type

  • 5.1 Introduction
  • 5.2 Mosaic Turner Syndrome
  • 5.3 Classical Turner Syndrome

6 Global Turner Syndrome Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Oxandrolone
  • 6.3 Oxandrin
  • 6.4 Norditropin
  • 6.5 Somatropin
  • 6.6 Genotropin
  • 6.7 Humatrope
  • 6.8 Zomacton
  • 6.9 Nutropin

7 Global Turner Syndrome Market, By Therapy Type

  • 7.1 Introduction
  • 7.2 Progesterone Replacement Therapy
  • 7.3 Oestrogen Replacement Therapy
  • 7.4 Growth Hormone Therapy
  • 7.5 Psychological Therapy
  • 7.6 Other Therapy Types

8 Global Turner Syndrome Market, By Diagnosis

  • 8.1 Introduction
  • 8.2 Physical Examination
  • 8.3 Karyotyping
  • 8.4 Prenatal Testing
    • 8.4.1 Amniocentesis
    • 8.4.2 Ultrasound Test
    • 8.4.3 Chorionic Villus Sampling
  • 8.5 Other Diagnosis

9 Global Turner Syndrome Market, By Route Of Administration

  • 9.1 Introduction
  • 9.2 Oral
  • 9.3 Sub-cutaneous
  • 9.4 Intravenous
  • 9.5 Intramuscular
  • 9.6 Other Route Of Administrations

10 Global Turner Syndrome Market, By End User

  • 10.1 Introduction
  • 10.2 Research Organizations
  • 10.3 Hospitals & Clinics
  • 10.4 Academic Institutes
  • 10.5 Other End Users

11 Global Turner Syndrome Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Smiths Group
  • 13.2 Pfizer Inc.
  • 13.3 Rocket Medical PLC
  • 13.4 Medtronic
  • 13.5 Novo Nordisk
  • 13.6 Sanofi
  • 13.7 Cooper Pharma
  • 13.8 Eli Lilly and Company
  • 13.9 Genentech
  • 13.10 Lupin Pharmaceuticals Inc
  • 13.11 Sandoz International GmbH
  • 13.12 AbbVie Inc.
  • 13.13 Codexis
  • 13.14 Merck & Co.
  • 13.15 American Gene Technologies
  • 13.16 Johnson & Johnson Services Inc
  • 13.17 F. Hoffmann-La Roche Limited
  • 13.18 Ultragenyx Pharmaceutical
  • 13.19 Abbott Laboratories
  • 13.20 BioMarin

List of Tables

  • Table 1 Global Turner Syndrome Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Turner Syndrome Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Turner Syndrome Market Outlook, By Mosaic Turner Syndrome (2021-2030) ($MN)
  • Table 4 Global Turner Syndrome Market Outlook, By Classical Turner Syndrome (2021-2030) ($MN)
  • Table 5 Global Turner Syndrome Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 6 Global Turner Syndrome Market Outlook, By Oxandrolone (2021-2030) ($MN)
  • Table 7 Global Turner Syndrome Market Outlook, By Oxandrin (2021-2030) ($MN)
  • Table 8 Global Turner Syndrome Market Outlook, By Norditropin (2021-2030) ($MN)
  • Table 9 Global Turner Syndrome Market Outlook, By Somatropin (2021-2030) ($MN)
  • Table 10 Global Turner Syndrome Market Outlook, By Genotropin (2021-2030) ($MN)
  • Table 11 Global Turner Syndrome Market Outlook, By Humatrope (2021-2030) ($MN)
  • Table 12 Global Turner Syndrome Market Outlook, By Zomacton (2021-2030) ($MN)
  • Table 13 Global Turner Syndrome Market Outlook, By Nutropin (2021-2030) ($MN)
  • Table 14 Global Turner Syndrome Market Outlook, By Therapy Type (2021-2030) ($MN)
  • Table 15 Global Turner Syndrome Market Outlook, By Progesterone Replacement Therapy (2021-2030) ($MN)
  • Table 16 Global Turner Syndrome Market Outlook, By Oestrogen Replacement Therapy (2021-2030) ($MN)
  • Table 17 Global Turner Syndrome Market Outlook, By Growth Hormone Therapy (2021-2030) ($MN)
  • Table 18 Global Turner Syndrome Market Outlook, By Psychological Therapy (2021-2030) ($MN)
  • Table 19 Global Turner Syndrome Market Outlook, By Other Therapy Types (2021-2030) ($MN)
  • Table 20 Global Turner Syndrome Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 21 Global Turner Syndrome Market Outlook, By Physical Examination (2021-2030) ($MN)
  • Table 22 Global Turner Syndrome Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 23 Global Turner Syndrome Market Outlook, By Prenatal Testing (2021-2030) ($MN)
  • Table 24 Global Turner Syndrome Market Outlook, By Amniocentesis (2021-2030) ($MN)
  • Table 25 Global Turner Syndrome Market Outlook, By Ultrasound Test (2021-2030) ($MN)
  • Table 26 Global Turner Syndrome Market Outlook, By Chorionic Villus Sampling (2021-2030) ($MN)
  • Table 27 Global Turner Syndrome Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 28 Global Turner Syndrome Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 29 Global Turner Syndrome Market Outlook, By Oral (2021-2030) ($MN)
  • Table 30 Global Turner Syndrome Market Outlook, By Sub-cutaneous (2021-2030) ($MN)
  • Table 31 Global Turner Syndrome Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 32 Global Turner Syndrome Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 33 Global Turner Syndrome Market Outlook, By Other Route Of Administrations (2021-2030) ($MN)
  • Table 34 Global Turner Syndrome Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 Global Turner Syndrome Market Outlook, By Research Organizations (2021-2030) ($MN)
  • Table 36 Global Turner Syndrome Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 37 Global Turner Syndrome Market Outlook, By Academic Institutes (2021-2030) ($MN)
  • Table 38 Global Turner Syndrome Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.